Allarity Therapeutics, Inc. (ALLR)
NASDAQ: ALLR · Real-Time Price · USD
1.190
+0.020 (1.71%)
At close: Jul 17, 2026, 4:00 PM EDT
1.150
-0.040 (-3.36%)
After-hours: Jul 17, 2026, 5:45 PM EDT
Allarity Therapeutics Employees
As of December 31, 2025, Allarity Therapeutics had 8 total employees, including 7 full-time and 1 part-time employees. The number of employees increased by 1 or 14.29% compared to the previous year.
Employees
8
Change (1Y)
1
Growth (1Y)
14.29%
Revenue / Employee
$43,125
Profits / Employee
-$1,406,125
Market Cap
18.93M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 8 | 1 | 14.29% | 7 | 1 |
| Dec 31, 2024 | 7 | 1 | 16.67% | 6 | 1 |
| Dec 31, 2023 | 6 | -3 | -33.33% | 5 | 1 |
| Dec 31, 2022 | 9 | -4 | -30.77% | 9 | 0 |
| Dec 31, 2021 | 13 | -1 | -7.14% | 13 | 0 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Pluri | 142 |
| Quince Therapeutics | 38 |
| Longeveron | 38 |
| Jasper Therapeutics | 22 |
| SeaStar Medical Holding | 17 |
| Atossa Therapeutics | 16 |
| Lipocine | 14 |
| Cellectar Biosciences | 11 |
ALLR News
- 10 days ago - Allarity Therapeutics Announces CLIA Certification, Clearing the Path for Advancing DRP® Testing for FDA Registration - GlobeNewsWire
- 17 days ago - Allarity Therapeutics Announces the Grant of Essential U.S. Patent for Its Stenoparib DRP® Companion Diagnostic - GlobeNewsWire
- 4 weeks ago - Allarity to present trial-in-progress poster on Phase 2 stenoparib trial - TheFly
- 4 weeks ago - Allarity Therapeutics to Present Trial-in-Progress Poster on Phase 2 Stenoparib Trial at ESMO Gynaecological Cancers Congress 2026 - GlobeNewsWire
- 2 months ago - Allarity Therapeutics Reports First Quarter 2026 Results and Continued Stenoparib Development in Multiple Cancers - GlobeNewsWire
- 2 months ago - Allarity Therapeutics CEO to Present at Precision Medicine Forum Europe 2026 in Stockholm - GlobeNewsWire
- 2 months ago - Allarity Therapeutics Advances Stenoparib Toward Pivotal Development with Phase 3 Manufacturing Campaign - GlobeNewsWire
- 2 months ago - Allarity receives notice of allowance from USPTO - TheFly